Acadia Pharmaceuticals Profit Margin

The latest profit margin for ACAD is 30.13% as of September 2026. That compares with 24.94% in the prior-year period — up 20.8% year over year. That is above the Healthcare sector average of 19.13%. Investors often review this figure alongside Acadia Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ACAD's profit margin moved from 24.94% to 30.13% — a 20.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acadia Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, ACAD currently prints 30.13% for profit margin, while the sector average sits near 19.13%. That is roughly 57.5% above the sector mean. Large gaps often invite a closer look at Acadia Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Acadia Pharmaceuticals converts resources into returns. At 30.13%, ACAD may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 24.94% in the prior-year period — up 20.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ACAD's profit margin (30.13%), review year-over-year change from 24.94%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.